Literature DB >> 21987471

High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease.

Ashley K Lotfipour1, Samuel Wharton, Stefan T Schwarz, V Gontu, Andreas Schäfer, Andrew M Peters, Richard W Bowtell, Dorothee P Auer, Penny A Gowland, Nin P S Bajaj.   

Abstract

PURPOSE: To determine if tissue magnetic susceptibility is a more direct marker of tissue iron content than other MR markers of iron. This study presents the first quantitative, in vivo measurements of the susceptibility of the substantia nigra in patients with Parkinson's disease.
MATERIALS AND METHODS: Nine patients and 11 controls were studied at 7 Tesla. Susceptibility maps were created by inverting the filtered phase maps associated with T2* weighted images.
RESULTS: On average, patients showed an increase in susceptibility of the pars compacta compared with controls, which correlates with the predicted increase in brain iron in Parkinson's disease. A rostral-caudal gradient in susceptibility was also observed in controls and patients.
CONCLUSION: Susceptibility mapping may provide a new tool for studying the development of Parkinson's disease.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21987471     DOI: 10.1002/jmri.22752

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  78 in total

Review 1.  Perspectives of Ultra-High-Field MRI in Neuroradiology.

Authors:  E R Gizewski; C Mönninghoff; M Forsting
Journal:  Clin Neuroradiol       Date:  2015-07-17       Impact factor: 3.649

2.  Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease.

Authors:  Y Murakami; S Kakeda; K Watanabe; I Ueda; A Ogasawara; J Moriya; S Ide; K Futatsuya; T Sato; K Okada; T Uozumi; S Tsuji; T Liu; Y Wang; Y Korogi
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-12       Impact factor: 3.825

Review 3.  Introduction to Quantitative Susceptibility Mapping and Susceptibility Weighted Imaging.

Authors:  Pascal P R Ruetten; Jonathan H Gillard; Martin J Graves
Journal:  Br J Radiol       Date:  2019-07-26       Impact factor: 3.039

Review 4.  Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.

Authors:  Adriane Gröger; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2012-08-09       Impact factor: 3.575

Review 5.  Contributions to magnetic susceptibility of brain tissue.

Authors:  Jeff H Duyn; John Schenck
Journal:  NMR Biomed       Date:  2016-05-30       Impact factor: 4.044

Review 6.  Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.

Authors:  Xiaojun Guan; Xiaojun Xu; Minming Zhang
Journal:  Neurosci Bull       Date:  2017-05-17       Impact factor: 5.203

Review 7.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

8.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

9.  Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease.

Authors:  Naying He; Pei Huang; Huawei Ling; Jason Langley; Chunlei Liu; Bei Ding; Juan Huang; Hongmin Xu; Yong Zhang; Zhongping Zhang; Xiaoping Hu; Shengdi Chen; Fuhua Yan
Journal:  NMR Biomed       Date:  2016-05-18       Impact factor: 4.044

10.  MR quantitative susceptibility imaging for the evaluation of iron loading in the brains of patients with β-thalassemia major.

Authors:  D Qiu; G C-F Chan; J Chu; Q Chan; S-Y Ha; M E Moseley; P-L Khong
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-27       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.